These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 26400824)

  • 1. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
    López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
    Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU; Newland A; McDonald V; Nandigam R; Mensah L; Leroy S; Seesaghur A; Patel H; Wetten S; Provan D
    Eur J Haematol; 2019 May; 102(5):416-423. PubMed ID: 30758874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
    Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
    Ghadaki B; Nazi I; Kelton JG; Arnold DM
    Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
    Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romiplostim as early treatment for refractory primary immune thrombocytopenia.
    Contis A; Lazaro E; Greib C; Pellegrin JL; Viallard JF
    Int J Hematol; 2013 Nov; 98(5):520-4. PubMed ID: 24068656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
    Al-Samkari H; Van Cott EM; Kuter DJ
    Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
    Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
    Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
    Raval JS; Redner RL; Kiss JE
    J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.